Savara Inc (SVRA): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

-$101.06M

Year ended 2025-12-31

-$110.66M

Trailing 12 months to 2026-06-30

2010-12-31 Free Cash Flow (USD) 2025-12-31

Period ended	Free Cash Flow	Change YoY	Source filing
2025-12-31	-$101.06M	n/m	2026-03-13, From 2025-01-01
2024-12-31	-$89.11M	n/m	2026-03-13, From 2024-01-01
2023-12-31	-$51.36M	n/m	2025-03-27, From 2023-01-01
2022-12-31	-$34.56M	n/m	2024-03-07, From 2022-01-01
2021-12-31	-$40.14M	n/m	2023-03-30, From 2021-01-01
2020-12-31	-$39.88M	n/m	2022-03-30, From 2020-01-01
2019-12-31	-$45.27M	n/m	2021-03-10, From 2019-01-01
2018-12-31	-$39.42M	n/m	2020-03-12, From 2018-01-01
2017-12-31	-$28.73M	n/a	2019-03-13, From 2017-01-01
No annual figure between 2013-12-31 and 2017-12-31.
2013-12-31	-$17.84M	n/m	2015-03-24, From 2013-01-01
2012-12-31	-$14.19M	n/m	2014-03-26, From 2012-01-01
2011-12-31	-$13.88M	n/m	2013-03-19, From 2011-01-01
2010-12-31	-$8.37M	n/a	2012-03-08, From 2010-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Free Cash Flow	Change YoY
Savara Inc (SVRA)	2025-12-31	-$101.06M	n/m
Heron Therapeutics, Inc. (HRTX)	2025-12-31	-$27.91M	n/m
Macrogenics Inc (MGNX)	2025-12-31	-$82.95M	n/m
Assembly Biosciences, Inc. (ASMB)	2025-12-31	-$41.16M	n/m
Phathom Pharmaceuticals, Inc. (PHAT)	2025-12-31	-$167.00M	n/m
Verastem, Inc. (VSTM)	2024-12-31	-$104.80M	n/a
Nature's Sunshine Products Inc (NATR)	2025-12-31	$28.84M	+101.3%
Perspective Therapeutics, Inc. (CATX)	2025-12-31	-$95.23M	n/m
Crescent Biopharma, Inc. (CBIO)	2025-12-31	-$72.45M	n/m

Compare SVRA, HRTX, MGNX, ASMB side by side · Screen every company in Pharmaceutical Preparations ↗